Latest Insider Transactions at Olema Pharmaceuticals, Inc. (OLMA)
This section provides a real-time view of insider transactions for Olema Pharmaceuticals, Inc. (OLMA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Olema Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Olema Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 23
2020
|
Cyrus Harmon |
BUY
Conversion of derivative security
|
Indirect |
122,028
+50.0%
|
-
|
|
Nov 23
2020
|
Cyrus Harmon |
BUY
Conversion of derivative security
|
Direct |
71,374
+6.03%
|
-
|
|
Nov 23
2020
|
Peter J. Kushner CHIEF SCIENTIFIC OFFICER |
BUY
Conversion of derivative security
|
Direct |
358,920
+11.64%
|
-
|
|
Nov 23
2020
|
Frank Mccormick Director |
BUY
Conversion of derivative security
|
Indirect |
66,326
+44.05%
|
-
|
|
Nov 23
2020
|
Frank Mccormick Director |
BUY
Conversion of derivative security
|
Direct |
152,891
+44.44%
|
-
|
|
Nov 23
2020
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
BUY
Conversion of derivative security
|
Indirect |
167,677
+50.0%
|
-
|
|
Nov 23
2020
|
Andrew Rappaport |
BUY
Conversion of derivative security
|
Indirect |
448,556
+34.42%
|
-
|
|
Nov 23
2020
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
1,160,000
+50.0%
|
$22,040,000
$19.0 P/Share
|
|
Nov 23
2020
|
G. Walmsley Graham |
BUY
Conversion of derivative security
|
Indirect |
2,583,875
+50.0%
|
-
|
|
Nov 23
2020
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
425,000
+11.5%
|
$8,075,000
$19.0 P/Share
|
|
Nov 23
2020
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
2,845,544
+50.0%
|
-
|
|
Nov 19
2020
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
1,135,334
+15.01%
|
$21,571,346
$19.0 P/Share
|
|
Nov 19
2020
|
Bvf Partners L P Director |
BUY
Conversion of derivative security
|
Direct |
5,216,676
+32.82%
|
-
|
|
Sep 23
2020
|
Sean Bohen President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,649
+50.0%
|
$206,596
$4.82 P/Share
|
|
Sep 16
2020
|
Cynthia M Butitta |
BUY
Exercise of conversion of derivative security
|
Direct |
83,876
+50.0%
|
$335,504
$4.41 P/Share
|
|
Jun 15
2020
|
Cyrus Harmon |
BUY
Grant, award, or other acquisition
|
Direct |
143,472
+12.12%
|
-
|
|
Jun 15
2020
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Grant, award, or other acquisition
|
Direct |
358,680
+50.0%
|
-
|
|
Jun 15
2020
|
Peter J. Kushner CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
143,472
+11.8%
|
-
|
|
Jun 15
2020
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
BUY
Grant, award, or other acquisition
|
Direct |
143,472
+19.51%
|
-
|